Skip to main content
Premium Trial:

Request an Annual Quote

Fisher Posts Double-Digit Increase in Q3 Revenues, Profit as it Awaits Thermo Merger

NEW YORK (GenomeWeb News) - Fisher Scientific yesterday reported a 10.8 percent increase in third-quarter sales and a 62 percent spike in income.
 
For the quarter ended Sept. 30, Fisher posted net sales of $1.51 billion as compared to $1.36 billion for the same quarter in 2005.
 
Net income increased to $152 million from $93.5 million last year.
 
Sales of scientific products and services in the third quarter increased to $1.17 billion, a 9.9 percent increase over the prior-year period, Fisher said.
 
As of Sept. 30, Fisher held $279 million in cash and equivalents.
 
Fisher is awaiting approval from the European Commission, which it expects by Nov. 9, to finalize its merger with Thermo Electron.
 
For 2006, Fisher said it expects total sales growth, excluding the effects of foreign exchange, of approximately 10 percent, with organic growth in its core scientific research and healthcare markets of 8 percent.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.